Table 1.
Baseline demographics, disease and clinical characteristics by line-of-treatment category
| Demographic characteristics | N | First-line n = 118 | Second-line n = 996 | Overall n = 1114 |
|---|---|---|---|---|
| Age, mean (SD) |
1113 |
59.1 (13.7) |
56.2 (12.4) |
56.5 (12.6) |
| Female, n (%) |
1114 |
82 (69.5) |
822 (82.5) |
904 (81.1) |
| Weight, mean (SD) |
1102 |
75.5 (15.9) |
74.5 (17.0) |
74.6 (16.9) |
|
Disease characteristics |
|
|
|
|
| Mean disease duration, years (SD) |
1079 |
6.9 (7.7) |
11.5 (8.9) |
11.0 (8.9) |
| Disease duration, n (%) |
|
|
|
|
| ≤2 years |
41 (35.3) |
100 (10.4) |
141 (13.1) |
|
| 3–5 years |
30 (25.9) |
200 (20.8) |
230 (21.3) |
|
| 6–10 years |
21 (18.1) |
242 (25.1) |
263 (24.4) |
|
| >10 years |
24 (20.7) |
421 (43.7) |
445 (41.2) |
|
|
Previous treatments |
|
|
|
|
| Previously treated with biologic agents, n (%) |
1114 |
0 (0.0) |
996 (100) |
996 (89.4) |
| At least one anti-TNF agent, n (%) |
0 (0.0) |
978 (98.2) |
978 (87.8) |
|
| Anti-TNF only |
0 (0.0) |
790 (79.3) |
790 (70.9) |
|
| Anti-TNF and another biologic |
0 (0.0) |
188 (18.9) |
188 (16.9) |
|
| Other mechanisms of action only |
0 (0.0) |
18 (1.8) |
18 (1.6) |
|
| Number of prior anti-TNF agents, mean (SD) |
0 (0.0) |
1.6 (0.7) |
1.4 (0.8) |
|
| One, n (%) |
0 (0.0) |
480 (48.2) |
480 (43.1) |
|
| Two, n (%) |
0 (0.0) |
405 (40.7) |
405 (36.4) |
|
| Three, n (%) |
0 (0.0) |
93 (9.3) |
93 (8.3) |
|
|
Clinical characteristics |
N* |
First-line N = 111 |
Second-line N = 968 |
Overall N = 1079 |
| Tender joint count (28), mean (SD) |
1052 |
11.5 (7.3) |
11.4 (7.3) |
11.4 (7.3) |
| Swollen joint count (28), mean (SD) |
1069 |
9.5 (5.8) |
7.8 (5.8) |
8.0 (5.9) |
| Patient global assessment, mean (SD) (VAS 100 mm) |
1002 |
61.9 (22.1) |
66.2 (20.1) |
65.8 (20.3) |
| Physician global assessment, mean (SD) (VAS 100 mm) |
937 |
61.9 (18.7) |
61.8 (19.4) |
61.8 (19.3) |
| Patient global assessment of pain, mean (SD) (VAS 100 mm) |
990 |
59.9 (24.5) |
65.9 (20.7) |
65.3 (21.1) |
| Patients with erosions, n (%) |
926 |
58 (58.0) |
590 (71.4) |
648 (70.0) |
| DAS28 (ESR), mean (SD) |
748 |
5.5 (1.3) |
5.6 (1.2) |
5.6 (1.2) |
| DAS28 (CRP), mean (SD) |
216 |
4.8 (1.1) |
5.2 (1.3) |
5.2 (1.3) |
| CDAI, mean (SD) |
919 |
33.4 (13.1) |
31.5 (13.0) |
31.7 (13.0) |
| SDAI, mean (SD) |
824 |
35.4 (13.8) |
33.9 (13.8) |
34.0 (13.8) |
| HAQ-DI, mean (SD) |
988 |
1.42 (0.59) |
1.56 (0.67) |
1.55 (0.67) |
| CRP mg/L, mean (SD) |
943 |
19.6 (32.5) |
24.4 (40.6) |
23.9 (39.9) |
| ESR mm/hour, mean (SD) |
988 |
32.5 (23.6) |
35.5 (24.5) |
35.2 (24.4) |
| Rheumatoid factor positive, n (%) |
886 |
64 (68.1) |
549 (69.3) |
613 (69.2) |
| Anti-CCP positive, n (%) | 598 | 36 (59.0) | 354 (65.9) | 390 (65.2) |
*All patients with relevant baseline data assessed no later than 8 days after the first infusion of abatacept.
CCP, anti-cyclic citrullinated protein; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; SD, standard deviation; SDAI, Simplified Disease Activity Index; TNF, tumor necrosis factor; VAS, visual analog scale.